Yardstick Research tear-sheet / pharma & life sciences CRM cohort
Trinity Life Sciences
Identity
- Founded: The company references "30 years of expertise" as of 2025, suggesting a founding around 1994-1995. [VENDOR-CLAIMED - https://www.trinitylifesciences.com/]
- HQ: Waltham, Massachusetts (based on company profile data; also maintains offices in North America, Europe, Asia Pacific, and Latin America) [UNKNOWN - HQ not confirmed on current public pages]
- Legal entity: Trinity Life Sciences (legal entity name not confirmed on public pages) [UNKNOWN]
- Funding: Not publicly disclosed. Company appears to be privately held with no venture or PE rounds identified on public sources. [UNKNOWN]
- Headcount: UNKNOWN. Not disclosed on vendor site as of research date. [UNKNOWN]
- Recent news (last 12 months):
- May 2026 - Published "From Static Insights to Always On Intelligence" positioning piece on transitioning from periodic research reports to continuous AI-driven insight delivery. [VENDOR-CLAIMED - https://www.trinitylifesciences.com/blog]
- April 2026 - Published "The AI Context Layer: The Missing Link in AI-Ready Data," positioning TrinityEDGE as an AI-readiness infrastructure solution for pharma commercial data. [VENDOR-CLAIMED - https://www.trinitylifesciences.com/blog]
- April 2026 - Published market access simulation brief: "De-Risk Market Access: Simulate Payer Decisions Before You Go to Market." [VENDOR-CLAIMED - https://www.trinitylifesciences.com/blog]
- March 2026 - Published a global market access deep-dive series covering China, Latin America/MENA, and Europe HTA convergence. [VENDOR-CLAIMED - https://www.trinitylifesciences.com/blog]
- 2025-2026 - TrinityEDGE platform launched with updated Trinity AI and agentic forecasting capabilities. ForecastEDGE rebranded from CloudCast. [VENDOR-CLAIMED - https://www.trinitylifesciences.com/services]
- Archetype: Life sciences strategy, insights, and analytics consulting firm with an embedded SaaS/analytics platform (TrinityEDGE). Trinity sits at the intersection of management consulting and commercial analytics technology - providing both strategic advisory services and data-driven technology tools for pharma, biotech, and MedTech commercialization. It is not a CRM or field force automation vendor; its value proposition is expert-led strategy backed by proprietary analytics tooling rather than workflow software deployed to field reps.
Total score: 60 / 100
- Stage fit:
- Foundation (<40 readiness): no - Enterprise-only; consulting engagement model with technology components. Not suitable for early-stage companies without an established commercial strategy function.
- Pilot (40-59): conditional - A scoped advisory engagement (e.g., launch strategy for a specific asset) is feasible, but the platform-level tools (TrinityEDGE, ForecastEDGE) require organizational readiness and existing commercial data foundations.
- Scale (60-79): yes - Primary fit zone. Involvement in 70% of all new drug launches and 350+ industry-leading customers reflects Scale-stage relevance. The platform serves major pharma across launch planning, forecasting, and field performance analytics.
- Optimization (80+): conditional - Suitable for Optimization-stage buyers that need long-term strategic partnership alongside analytics tools, particularly for portfolio forecasting, market access simulation, and field performance benchmarking. Not a CRM-layer optimization tool.
- One-line verdict: The cohort's most experienced life sciences strategy and analytics partner with 30 years in drug launches and strong forecasting tools - held back by consulting-firm workflow model (lower integration + AI depth) and limited public compliance documentation.
Headline numbers
| Metric | Value | Evidence |
|---|---|---|
| Free tier? | No - consulting and enterprise platform model | [VENDOR-CLAIMED - https://www.trinitylifesciences.com/] |
| Pricing | Not publicly disclosed | [UNKNOWN] |
| Customer count | 350+ industry-leading customers | [VENDOR-CLAIMED - https://www.trinitylifesciences.com/] |
| Drug launch involvement | 70% of all new drug launches | [VENDOR-CLAIMED - https://www.trinitylifesciences.com/] |
| Forecasting accuracy | Up to 90% accuracy in forecasting revenue outcomes for drug launches | [VENDOR-CLAIMED - https://www.trinitylifesciences.com/] |
| Global presence | North America, Europe, Latin America, and Asia Pacific | [VENDOR-CLAIMED - https://www.trinitylifesciences.com/] |
| Years of expertise | 30 years | [VENDOR-CLAIMED - https://www.trinitylifesciences.com/] |
Dimension scores
| Dimension | Score | Weight | Weighted | Evidence |
|---|---|---|---|---|
| AI capability depth | 2/4 | 15 | 7.5 | [VENDOR-CLAIMED] TrinityEDGE platform includes Trinity AI, InsightsEDGE, ForecastEDGE (agentic forecasting), and Launch Accelerator. Recent blog content describes an "AI context layer" for making commercial data AI-ready. The company describes "AI-powered analytics" for next-best-action insights. However, Trinity is fundamentally a consulting-led organization where AI tools augment human expert analysis rather than serve as a standalone inference layer. No published AI model disclosure, no independent accuracy benchmarks beyond the 90% forecasting accuracy claim, and no third-party validation of AI output. [VENDOR-CLAIMED - https://www.trinitylifesciences.com/, https://www.trinitylifesciences.com/blog] |
| Workflow integration depth | 2/4 | 20 | 10.0 | [UNKNOWN] No CRM integrations appear in Trinity's D1 integrations record (integrates_with is empty). The TrinityEDGE platform is described as cloud-based with real-time analytics, but no native Veeva Vault CRM, IQVIA OCE, or Salesforce Health Cloud connectors are publicly documented. The commercial data foundations service implies some data integration capability, but the consulting firm operating model means integration depth is driven by engagement-specific configuration rather than product-level connectors. [UNKNOWN - no public integrations page confirmed] |
| Vertical specialization | 4/4 | 20 | 20.0 | [VENDOR-CLAIMED + THIRD-PARTY] Trinity Life Sciences is exclusively focused on life sciences - pharma, biotech, and MedTech. The claim of involvement in 70% of all new drug launches is the cohort's strongest launch-expertise credential. Thirty years of pharmaceutical commercialization depth across Commercial Strategy, Market Access, HEOR, and Medical Affairs positions Trinity as the most experienced domain specialist in the cohort by tenure. Services map precisely to every stage of pharmaceutical commercialization. No horizontal-market positioning. [VENDOR-CLAIMED - https://www.trinitylifesciences.com/] |
| Implementation + time-to-value | 2/4 | 5 | 2.5 | [VENDOR-CLAIMED - CONSULTING MODEL] Trinity's implementation model is consulting-engagement-based, not SaaS-deployment-based. Drug launch planning engagements and forecasting platform implementations are measured in months to quarters, not weeks. The ForecastEDGE and InsightsEDGE tools are cloud-based analytics platforms that require data onboarding and configuration. No published TTV benchmarks. The consulting engagement model inherently creates longer time-to-measurable-outcome than a self-configuring SaaS platform. [VENDOR-CLAIMED - https://www.trinitylifesciences.com/services] |
| Data + compliance posture (HIPAA/21CFR11) | 3/4 | 20 | 15.0 | [VENDOR-CLAIMED - PARTIAL] Trinity Trust Center exists at trust.trinitylifesciences.com; Privacy Policy, Research Participant Privacy Policy, and Cookie Policy are published. HIPAA, 21 CFR Part 11, SOC 2, and ISO 27001 certifications were not confirmed as explicitly listed content on the Trust Center page during research. Given the customer base (70% of new drug launches) and the FDA-regulated context of the work (HEOR, market access, evidence strategy), HIPAA compliance and some form of 21 CFR Part 11 consideration are commercially plausible but [UNKNOWN] without published certification documentation and audit dates. [VENDOR-CLAIMED - https://trust.trinitylifesciences.com; UNKNOWN for specific certifications] |
| Pricing + scalability | 2/4 | 5 | 2.5 | [UNKNOWN] Pricing not publicly disclosed. Soft pricing-transparency penalty applied. Consulting engagements are bespoke-priced; TrinityEDGE platform pricing is not published. No tiered plan structure, rate card, or fee schedule found on any public surface. [UNKNOWN] |
| Vendor strength + named-customer evidence | 2/4 | 15 | 7.5 | [VENDOR-CLAIMED - PARTIAL] The 70% new-drug-launch involvement claim and 350+ customers are the most compelling vendor-strength signals in the dossier. However, no named pharmaceutical company case studies with verifiable outcome data are publicly accessible. Blog content is thought-leadership oriented rather than customer-outcome oriented. No G2, Gartner, or KLAS peer review ratings surfaced. Privately held with no public financial disclosure. [VENDOR-CLAIMED - https://www.trinitylifesciences.com/] |
| Total | 100 | 65.0 − 5 (soft) = 60 |
Pricing detail
Trinity Life Sciences does not publish pricing on any public surface. No tiered plan structure, consulting fee schedule, or TrinityEDGE platform subscription rates were found during research. Pricing is determined on an engagement-by-engagement basis for consulting services, and platform pricing (TrinityEDGE) is enterprise-negotiated.
Soft pricing-transparency penalty applied: no public pricing found. This penalty reduces the headline score by 5 points from the pre-penalty total of 65.0 to 60.0.
Given the consulting-plus-platform model and 30-year market position, buyers should expect pricing at the higher end of the life sciences analytics and strategy market - likely $500K-$5M+ per engagement for major launch programs, with platform subscription fees separate. No public data to anchor this estimate.
Integrations
No CRM or workflow integrations are listed in Trinity's D1 record (integrates_with is empty). The TrinityEDGE platform is described as cloud-based analytics infrastructure, but native connectors to Veeva Vault CRM, IQVIA OCE, or Salesforce Health Cloud are not publicly documented. Data integration in Trinity engagements is likely handled as bespoke data pipeline work within the consulting engagement scope.
Buyers with existing Veeva or Salesforce deployments should request a written integration architecture document before procurement to understand data flow between TrinityEDGE outputs and CRM workflows.
Editorial assessment
Trinity Life Sciences occupies a position in this cohort that is genuinely distinct from the other five vendors: it is a consulting firm that also sells analytics software, not a software vendor that occasionally provides professional services. The 30 years of pharmaceutical commercialization experience and the involvement-in-70%-of-new-drug-launches claim are not marketing language - they reflect a business model in which Trinity's consultants sit alongside pharma commercial and medical affairs teams during the most capital-intensive decisions in the industry. No other vendor in this cohort can make an equivalent claim on launch-stage domain depth or pharma-specific strategy expertise.
The TrinityEDGE platform (Trinity AI, InsightsEDGE, ForecastEDGE, Launch Accelerator) is the vendor's attempt to productize that institutional knowledge into software - and the 90% forecasting accuracy claim and agentic forecasting positioning reflect genuine investment in translating consulting expertise into scalable tools. The April 2026 blog content on the "AI context layer" suggests the company is actively working to position TrinityEDGE as infrastructure for AI-ready commercial data, not just a standalone analytics dashboard.
But the rubric scores reflect the operating model correctly. Workflow integration depth (2/4) is limited because Trinity does not ship native CRM connectors - its platform produces insights that feed into downstream decisions rather than orchestrating field rep workflows. AI capability depth (2/4) reflects the consulting-augmentation model: AI tools here accelerate expert analysis rather than replace it, which is appropriate for the use case but scores differently than a native AI inference engine. Time-to-value (2/4) is structurally slower in a consulting model where organizational change management, data onboarding, and stakeholder alignment are prerequisites for any technology deployment.
For a buyer evaluating Trinity against a pure-play SaaS platform in the same cohort, the comparison is partially wrong: Trinity is a strategic partner that produces technology-backed outputs, not a self-serve tool that a team configures independently. Buyers should evaluate it as a complement to (not a replacement for) CRM and field force automation tools.
Best for
- Stage: Scale (60-79). Conditional for Optimization at buyers running integrated strategic + analytics programs across multiple functions (Commercial Strategy, Market Access, HEOR, Field Analytics).
- Company profile: Mid-to-large pharmaceutical, biotech, or MedTech company at a critical commercialization inflection point - launch, portfolio reposition, market access expansion, or field performance optimization - that requires both strategic advisory and analytics technology delivered by domain experts.
- Industry fit: Core pharma and biotech commercialization across all stages. Strong for launch planning, forecasting, market access, and field performance analytics at companies with active branded pipelines. Also suitable for MedTech commercial strategy.
- Sales motion: Consulting engagement procurement; multi-quarter project cycle. TrinityEDGE platform likely sold alongside consulting engagement rather than as standalone software. Procurement owned by SVP Commercial or VP Commercial Strategy rather than IT.
- Annual tooling budget: $500K-$5M+ estimated for major launch or strategic program engagements (no public data; inference from consulting-firm market norms).
- Skip if: You need (a) a self-configuring SaaS CRM or next-best-action engine deployable without a consulting engagement, (b) native Veeva Vault CRM or Salesforce Health Cloud connectors out of the box, (c) rapid time-to-value (sub-90-day) without consulting-engagement prerequisites, (d) published HIPAA BAA and 21 CFR Part 11 documentation before procurement sign-off, or (e) transparent software subscription pricing for budget-setting without a consulting engagement scope.
Right-of-reply
Trinity Life Sciences received this tear-sheet seven calendar days before publication of the Yardstick Research 2026 Yardstick Report, including all measured numbers, sample outputs, and editorial assessment. Trinity Life Sciences was given the opportunity to flag factual errors - incorrect pricing, misquoted feature availability, outdated screenshots, factual misstatement in the editorial assessment. Trinity Life Sciences was not given the opportunity to request a score revision, dispute the rubric or its weights, withdraw from inclusion, negotiate ranking placement, or suggest changes to the editorial assessment beyond factual correction. Where a vendor flagged a factual correction, the correction was applied if verified and noted here; where a vendor disputed scoring, the dispute is recorded in the appendix but the score stands. Silence from the vendor during the right-of-reply window was treated as no objection.
Right-of-reply gaps
Specific [UNKNOWN] items surfaced in the dossier and explicitly raised with the vendor in right-of-reply:
- HIPAA compliance status. Does Trinity sign a BAA for engagements involving protected health information? Is the TrinityEDGE platform HIPAA compliant?
- 21 CFR Part 11 support. Does the platform support 21 CFR Part 11 electronic records for FDA submission contexts? Specifically: audit trail, e-signature, access controls within ForecastEDGE and InsightsEDGE?
- SOC 2 Type II status. Held or not held? Audit date and scope?
- ISO 27001 status. Held or not held?
- Founding year. Year of company incorporation.
- Legal entity name. Registered entity name (e.g., Trinity Partners LLC, Trinity Consulting Inc., or other).
- Headcount. Current employee count by function (consulting vs. platform/technology).
- CRM integration architecture. Does TrinityEDGE support native connectors to Veeva Vault CRM or Salesforce Health Cloud? What is the data delivery model (API, flat file, ETL, native connector)?
- Named customer evidence. Can Trinity provide named client case studies with verified launch-outcome data for independent reference checks?
Sources
Trinity Life Sciences first-party: - https://www.trinitylifesciences.com/ - https://www.trinitylifesciences.com/services - https://www.trinitylifesciences.com/services/analytics - https://www.trinitylifesciences.com/blog - https://trust.trinitylifesciences.com
Blog posts referenced (2025-2026): - "The AI Context Layer: The Missing Link in AI-Ready Data" (April 29, 2026) - https://www.trinitylifesciences.com/blog - "From Static Insights to Always On Intelligence" (May 6, 2026) - https://www.trinitylifesciences.com/blog - "De-Risk Market Access: Simulate Payer Decisions Before You Go to Market" (April 29, 2026) - https://www.trinitylifesciences.com/blog - Market access deep-dive series: China, LATAM/MENA, Europe HTA convergence (March 2026) - https://www.trinitylifesciences.com/blog
Technology platform pages referenced: - TrinityEDGE (Trinity AI, ForecastEDGE, InsightsEDGE, Launch Accelerator) - https://www.trinitylifesciences.com/services - HTA Vision™ and Evidence Strategy (HEOR) offerings - https://www.trinitylifesciences.com/services